Using RNA Therapies to Target Inherited Retinal Diseases

Daniel de Boer, CEO of ProQR Therapeutics, discusses the evolution of his company, its pipeline of antisense oligonucleotide therapies, and the advantage of this approach in treating rare eye diseases.